WELCOME TO THE AMGEN BOOTH.

THANK YOU FOR VISITING, .

Click below to access further publications on tarlatamab

Tarlatamab in SCLC after Platinum Chemotherapy

Giannis Mountzios et al. (Download NEJM Paper)

Management of adverse events in patients receiving tarlatamab for SCLC

Jacob Sands et al. (Download Review)

Download DeLLphi-304 Slides

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates